Big Pharma Launches into RNAi

Tuma, Rabiya S.
September 2006
Pharma DD: Tracking Discovery & Development;Sep/Oct2006, Vol. 1 Issue 2, p40
Academic Journal
The article focuses on RNA interference (RNAi) deals of pharmaceutical companies. Treatment of a disease in a fundamentally different way than prior approaches can be made by Alnylam with the use of RNAi according to chief operating officer Barry Greene. Bill Kohlbrenner, director of cancer research discovery at Abbott Laboratories, says that everyone recognizes that the delivery of small interfering RNA into diseased cells is the big technical hurdle to the technology.


Related Articles

  • Small RNAs: siRNA as a sponge. Baker, Monya // Nature Methods;Apr2012, Vol. 9 Issue 4, p327 

    The article offers information on a research related to development of a delivery vehicle made from RNA molecules which helps short interfering RNAs (siRNAs) to reach the intended cells.

  • Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Robbins, Marjorie A.; Mingjie Li; Leung, Irene; Haitang Li; Boyer, Doris V.; Yong Song; Behlke, Mark A.; Rossi, John J. // Nature Biotechnology;May2006, Vol. 24 Issue 5, p566 

    RNA interference occurs when cytoplasmic small interfering RNAs (siRNAs) enter the RNA-induced silencing complex and one strand guides cleavage of the target RNA by the Argonaute 2 protein. A significant concern when applying siRNAs or expressing small hairpin RNAs (shRNAs) in human cells is...

  • Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Shammas, Masood A.; Koley, Hemanta; Batchu, Ramesh B.; Bertheau, Robert C.; Protopopov, Alexei; Munshi, Nikhil C.; Goyal, Raj K. // Molecular Cancer;2005, Vol. 4, p24 

    Background: In cancer cells, telomerase induction helps maintain telomere length and thereby bypasses senescence and provides enhanced replicative potential. Chemical inhibitors of telomerase have been shown to reactivate telomere shortening and cause replicative senescence and apoptotic cell...

  • RNA Interference with Chemically Modified siRNA. Hong-Yan Zhang; Quan Du; Wahlestedt, Claes; Zicai Liang // Current Topics in Medicinal Chemistry;May2006, Vol. 6 Issue 9, p893 

    siRNA has become an indispensable tool for functional characterization of genes. It has also demonstrated tremendous potential as a new generation of drug candidates. Although the technology works very well to a great panel of cells in vitro, it is still a challenge to translate the success into...

  • TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. Haase, Astrid D.; Jaskiewicz, Lukasz; Zhang, Haidi; Lainé, Sébastien; Sack, Ragna; Gatignol, Anne; Filipowicz, Witold // EMBO Reports;Oct2005, Vol. 6 Issue 10, p961 

    Dicer is a key enzyme involved in RNA interference (RNAi) and microRNA (miRNA) pathways. It is required for biogenesis of miRNAs and small interfering RNAs (siRNAs), and also has a role in the effector steps of RNA silencing. Apart from Argonautes, no proteins are known to associate with Dicer...

  • Efficient Delivery of siRNA Targeted Against Human Papillomavirus Oncogenes. Wise-Draper, Trisha M.; Wells, Susanne I. // Pharmaceutical Discovery;May2005 Supplement, Vol. 5, p27 

    The article evaluates the efficiency of transfection reagents in the delivery of small interfering RNA targeted against human papillomavirus (HPV). The X-tremeGENE small interfering Transfection Reagent has a transfection efficiency of 80 to 90 percent. A reduction of HPV18 E6⁄E7 messenger...

  • Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Unwalla, Hoshang J; Ming-Jie Li; Kim, James D.; Hai Tang Li; Ehsani, Ali; Alluin, Jessica; Rossi, John J // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1573 

    Here we demonstrate that an inducible anti-HIV short hairpin RNA (shRNA) expressed from a Pol II promoter inhibits HIV-1 gene expression in mammalian cells. Our strategy is based on a promoter system in which the HIV-1 LTR is fused to the Drosophila hsp70 minimal heat shock promoter. This system...

  • Non-cell-autonomous effects of vector-expressed regulatory RNAs in mammalian heart cells. Kizana, E.; Cingolani, E.; Marbán, E. // Gene Therapy;Sep2009, Vol. 16 Issue 9, p1163 

    In mammalian cells, small regulatory RNA molecules are able to modulate gene expression in a cell-autonomous manner. In contrast, this mechanism of gene regulation can occur systemically in plants and nematodes. The existence of similar cell-to-cell transmission in mammalian cells has been...

  • A universal RNAi-based logic evaluator that operates in mammalian cells. Rinaudo, Keller; Bleris, Leonidas; Maddamsetti, Rohan; Subramanian, Sairam; Weiss, Ron; Benenson, Yaakov // Nature Biotechnology;Jul2007, Vol. 25 Issue 7, p795 

    Molecular automata that combine sensing, computation and actuation enable programmable manipulation of biological systems. We use RNA interference (RNAi) in human kidney cells to construct a molecular computing core that implements general Boolean logic to make decisions based on endogenous...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics